Author: Udaykumar, Ranga Mangaiarkarasi Asokan
Title: Inducing quality immune response to respiratory viruses may not be a simple task Cord-id: rwu5rlgj Document date: 2021_1_1
ID: rwu5rlgj
Snippet: A few front-runner vaccines for COVID-19 have reported over 90% protection in phase II/III clinical trials, raising hopes. These studies, however, have evaluated only a relative, not absolute, protection. The leading COVID-19 vaccines have been designed to elicit a systemic, not mucosal, immune response. While a systemic immune response may reduce disease severity, only the mucosal immune response can reduce the spreading of a respiratory viral infection. Here, we explain why inducing long-lasti
Document: A few front-runner vaccines for COVID-19 have reported over 90% protection in phase II/III clinical trials, raising hopes. These studies, however, have evaluated only a relative, not absolute, protection. The leading COVID-19 vaccines have been designed to elicit a systemic, not mucosal, immune response. While a systemic immune response may reduce disease severity, only the mucosal immune response can reduce the spreading of a respiratory viral infection. Here, we explain why inducing long-lasting and high-quality immune response to mucosal infections is typically challenging. A few possible solutions are proposed.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date